BACKGROUND Hepatitis C virus infection is a global health problem. New direct-acting antiviral agents have been recently approved. However, due to their high cost and some genotypes remaining difficult to treat, interferon-based therapy with pegylated interferon and ribavirin likely may remain a component of hepatitis C virus treatment for some patients. Unfortunately, pegylated interferon / ri...

Hepatitis C virus genotype 2 (HCV-2) slow responders poorly respond to 24 weeks of peginterferon (Peg-IFN) plus ribavirin (RBV). We evaluated the efficacy of extended 48-week regimen and the role of interleukin-28B (IL-28B) genotype in this clinical setting. Treatment-naïve HCV-2 patients not achieving rapid virologic response (RVR) by Peg-IFN alfa-2a 180 μg/week plus weight-based RBV (1,000-1,...

In re: SUNTERRA CORPORATION SECURITIES LITIGATION. ) ) ) ) ) ) ) ) ) ) ) ) ) Case Nos. 6:00-cv-79-Orl-28B, 6:00-cv-97-Orl-28B, 6:00-cv-112Orl-28B, 6:00-cv115-Orl-28B, 6:00-cv-116-Orl28B, 6:00-cv-121-Orl-28B, 6:00cv-127-Orl-28B, 6:00-cv-128-Orl-28B, 6:00-cv-169Orl-28B, 6:00-cv-210-Orl-28B, 6:00-cv-268-Orl28B, 6:00-cv-278-Orl-28B, 6:00cv-285-Orl-28B, 6:00-cv-286-Orl28B, 6:00-cv321-Orl-28B

The aim of the present study was to predict sustained virological response (SVR) to telaprevir with pegylated interferon (PEG-IFN) and ribavirin using viral response within 2 weeks after therapy initiation. Thirty-six patients with genotype 1 hepatitis C virus (HCV) and high viral load were treated by telaprevir-based triple therapy. SVR was achieved in 72% (26/36) of patients. Significant diff...

A single-nucleotide polymorphism (SNP) upstream of interleukin (IL)28B was recently identified as an important predictor of the outcome of chronic hepatitis C patients treated with pegylated interferon plus ribavirin (PEG-IFN/RBV). The aim of this study was to investigate the association between the IL28B gene polymorphism (rs12979860) and virological response in chronic hepatitis C patients. B...

Interleukin 28B (IL28B) rs12979860 polymorphisms were examined in 41 individuals with human T-lymphotrophic virus type 1 (HTLV-1). The alleles CT/TT were more frequent in 12 individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis than in 29 asymptomatic carriers (80% vs 20%; P = .03), and median HTLV-1 proviral load was greater in CT/TT than CC carriers (P = .01). Thus, IL28B...

Concurrent infection with hepatitis C virus (HCV) and hepatitis B virus (HBV) was not uncommon in China. To date, information on predictors of response to treatment of dually-infected HCV/HBV is limited. The aim of this study was to evaluated whether determination of the interleukin 28B (IL-28B) polymorphism statuses sufficient to predict treatment response of interferon (IFN)-based therapy in ...

HCV infection is a serious public health problem and a leading cause of chronic liver disease. It affects nearly 3% of the world's population with an associated high mortality. Egypt has the highest prevalence of HCV infection in the world (estimated at >10%). Peg-IFN-α and RBV are the most widely used therapy for HCV. Unfortunately, the rate of SVR is around 50%. In addition, it is expensive a...